Roseburia spp.: A marker of health?

Future Microbiology

Volumn 12, Issue 2, 2017, Pages 157-170

  Tamanai Shacoori, Zohreh ^a   Smida, Imen ^a   Bousarghin, Latifa ^a   Loreal, Olivier ^a   Meuric, Vincent ^a,b,c   Fong, Shao Bing ^c   Bonnaure Mallet, Martine ^a,b,c   Jolivet Gougeon, Anne ^a,b,c  

^a Univ Rennes   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

butyrate; diet; irritable bowel syndrome; microbiota; nervous system; Roseburia spp.

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; PREBIOTIC AGENT; ANTIINFECTIVE AGENT; PROBIOTIC AGENT;

AGE; ANAEROBIC BACTERIUM; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIUM DETECTION; BACTERIUM EXAMINATION; DIABETES MELLITUS; DIET; DIGESTIVE SYSTEM; GALLSTONE; GRAM POSITIVE BACTERIUM; HEPATIC ENCEPHALOPATHY; HUMAN; IMMUNOPATHOLOGY; INTESTINE FLORA; INTESTINE FUNCTION; LIVER CIRRHOSIS; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; ROSEBURIA; SECRETION (PROCESS); TAXONOMY; VIRUS; CLASSIFICATION; GASTROINTESTINAL TRACT; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY;

ANTI-INFECTIVE AGENTS; DIABETES MELLITUS; DIET; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GRAM-POSITIVE BACTERIA; HUMANS; METABOLIC SYNDROME X; OBESITY; PREBIOTICS; PROBIOTICS;

EID: 85011301088     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2016-0130     Document Type: Review

References (123)

1. Dehingia M, Thangjam Devi K, Talukdar NC, et al. Gut bacterial diversity of the tribes of India and comparison with the worldwide data. Sci. Rep. 5, 18563 (2015).
2. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ. Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int. J. Syst. Evol. Microbiol. 52(Pt 5), 1615-1620 (2002).
3. Duncan SH, Aminov RI, Scott KP, Louis P, Stanton TB, Flint HJ. Proposal of Roseburia faecis sp. nov., Roseburia hominis sp. nov. and Roseburia inulinivorans sp. nov., based on isolates from human faeces. Int. J. Syst. Evol. Microbiol. 56(Pt 10), 2437-2441 (2006).
4. Stanton TB, Savage DC. Colonization of gnotobiotic mice by Roseburia cecicola, a motile, obligately anaerobic bacterium from murine ceca. Appl. Environ. Microbiol. 45(5), 1677-1684 (1983).
5. Stanton TB, Savage DC. Motility as a factor in bowel colonization by Roseburia cecicola, an obligately anaerobic bacterium from the mouse caecum. J. Gen. Microbiol. 130(1), 173-183 (1984).
6. Scott KP, Martin JC, Chassard C, et al. Substrate-driven gene expression in Roseburia inulinivorans: importance of inducible enzymes in the utilization of inulin and starch. Proc. Natl Acad. Sci. USA 108(Suppl. 1), 4672-4679 (2011).
7. Scott KP, Martin JC, Duncan SH, Flint HJ. Prebiotic stimulation of human colonic butyrate-producing bacteria and bifidobacteria, in vitro. FEMS Microbiol. Ecol. 87(1), 30-40 (2014).
8. Falony G, Vlachou A, Verbrugghe K, De Vuyst L. Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. Appl. Environ. Microbiol. 72(12), 7835-7841 2006).
9. Scott KP, Martin JC, Campbell G, Mayer CD, Flint HJ. Whole-genome transcription profiling reveals genes up-regulated by growth on fucose in the human gut bacterium "Roseburia inulinivorans". J. Bacteriol. 188(12), 4340-4349 (2006).
10. Sheridan PO, Martin JC, Lawley TD, et al. Polysaccharide utilization loci and nutritional specialization in a dominant group of butyrate-producing human colonic Firmicutes. Microb. Genomics 2(2), 1-16(2016).
11. Aminov RI, Walker AW, Duncan SH, Harmsen HJ, Welling GW, Flint HJ. Molecular diversity, cultivation, and improved detection by fluorescent in situ hybridization of a dominant group of human gut bacteria related to Roseburia spp. or Eubacterium rectale. Appl. Environ. Microbiol. 72(9), 6371-6376 (2006).
12. Furet JP, Firmesse O, Gourmelon M, et al. Comparative assessment of human and farm animal faecal microbiota using real-Time quantitative PCR. FEMS Microbiol. Ecol. 68(3), 351-362 (2009).
13. Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with Type 2 diabetes differs from non-diabetic adults. PLoS ONE 5(2), e9085 (2010).
14. Chang JY, Shin SM, Chun J, Lee JH, Seo JK. Pyrosequencing-based molecular monitoring of the intestinal bacterial colonization in preterm infants. J. Pediatr. Gastroenterol. Nutr. 53(5), 512-519 (2011).
15. Jost T, Lacroix C, Braegger CP, Chassard C. New insights in gut microbiota establishment in healthy breast fed neonates. PLoS ONE 7(8), e44595 (2012).
16. Jost T, Lacroix C, Braegger C, Chassard C. Assessment of bacterial diversity in breast milk using culture-dependent and cultureindependent approaches. Br. J. Nutr. 110(7), 1253-1262 (2013).
17. Jost T, Lacroix C, Braegger CP, Rochat F, Chassard C. Vertical mother-neonate transfer of maternal gut bacteria via breastfeeding. Environ. Microbiol. 16(9), 2891-2904 (2014).
18. Mäkivuokko H, Tiihonen K, Tynkkynen S, Paulin L, Rautonen N. The effect of age and non-steroidal anti-inflammatory drugs on human intestinal microbiota composition. Br. J. Nutr. 103(2), 227-234 (2010).
19. Claesson MJ, Jeffery IB, Conde S, et al. Gut microbiota composition correlates with diet and health in the elderly. Nature 488(7410), 178-184 (2012).
20. Wang F, Yu T, Huang G, et al. Gut microbiota community and its assembly associated with age and diet in Chinese centenarians. J. Microbiol. Biotechnol. 25(8), 1195-1204 2015).
21. Lukas F, Gorenc G, Kopecny J. Detection of possible AI-2-mediated quorum sensing system in commensal intestinal bacteria. Folia Microbiol. (Praha) 53(3), 221-224 (2008).
22. O'Connor LT, Savage DC. Characterization of an activity from the strict anaerobe Roseburia cecicola that degrades DNA when exposed to air. J. Bacteriol. 175(15), 4681-4687 (1993).
23. Hatziioanou D, Mayer MJ, Duncan SH, Flint HJ, Narbad A. A representative of the dominant human colonic Firmicutes, Roseburia faecis M72/1, forms a novel bacteriocin-like substance. Anaerobe 23, 5-8 2013).
24. Louis P, Flint HJ. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol. Lett. 294(1), 1-8 (2009).
25. Lachmandas E, van den Heuvel CN, Damen MS, Cleophas MC, Netea MG, van Crevel R. Diabetes mellitus and increased tuberculosis susceptibility: the role of short-chain fatty acids. J. Diabetes Res. 2016, 6014631 (2016).
26. Khemayanto H, Shi B. Role of Mediterranean diet in prevention and management of Type 2 diabetes. Chin. Med. J. (Engl) 127(20), 3651-3656 (2014).
27. Haro C, Montes-Borrego M, Rangel-Zúñiga OA, et al. Two healthy diets modulate gut microbial community improving insulin sensitivity in a human obese population. J. Clin. Endocrinol. Metab. 101(1), 233-242 2016).
28. Belenguer A, Duncan SH, Calder AG, et al. Two routes of metabolic cross-feeding between Bifidobacterium adolescentis and butyrate-producing anaerobes from the human gut. Appl. Environ. Microbiol. 72(5), 3593-3599 (2006).
29. Benus RF, Van Der Werf TS, Welling GW, et al. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br. J. Nutr. 104(5), 693-700 (2010).
30. Kabeerdoss J, Devi RS, Mary RR, Ramakrishna BS. Faecal microbiota composition in vegetarians: comparison with omnivores in a cohort of young women in southern India. Br. J. Nutr. 108(6), 953-957 2012).
31. Zhou XL, Kong XF, Lian GQ, Blachier F, Geng MM, Yin YL. Dietary supplementation with soybean oligosaccharides increases short-chain fatty acids but decreases protein-derived catabolites in the intestinal luminal content of weaned Huanjiang mini-piglets. Nutr. Res. 34(9), 780-788 2014).
32. Murtaza N, Baboota RK, Jagtap S, et al. Finger millet bran supplementation alleviates obesity-induced oxidative stress, inflammation and gut microbial derangements in high-fat diet-fed mice. Br. J. Nutr. 112(9), 1447-1458 (2014).
33. Gullon P, Gullon B, Tavaria F, Vasconcelos M, Gomes AM. In vitro fermentation of lupin seeds (Lupinus albus) and broad beans (Vicia faba): dynamic modulation of the intestinal microbiota and metabolomic output. Food Funct. 6(10), 3316-3322 (2015).
34. Dabek M, McCrae SI, Stevens VJ, Duncan SH, Louis P. Distribution of beta-glucosidase and beta-glucuronidase activity and of beta-glucuronidase gene gus in human colonic bacteria. FEMS Microbiol. Ecol. 66(3), 487-495 (2008).
35. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl Acad. Sci. USA 107(33), 14691-14696 (2010).
36. Chassard C, Bernalier-Donadille A. H2 and acetate transfers during xylan fermentation between a butyrate-producing xylanolytic species and hydrogenotrophic microorganisms from the human gut. FEMS Microbiol. Lett. 254(1), 116-122 (2006).
37. Ramsay AG, Scott KP, Martin JC, Rincon MT, Flint HJ. Cell-Associated alpha-Amylases of butyrate-producing Firmicute bacteria from the human colon. Microbiology 152(Pt 11), 3281-3290 (2006).
38. Comfort D, Clubb RT. A comparative genome analysis identifies distinct sorting pathways in gram-positive bacteria. Infect. Immun. 72(5), 2710-2722 (2004).
39. Charrier C, Duncan GJ, Reid MD, et al. A novel class of CoA-Transferase involved in short-chain fatty acid metabolism in butyrate-producing human colonic bacteria. Microbiology 152(Pt 1), 179-185 (2006).
40. Louis P, Young P, Holtrop G, Flint HJ. Diversity of human colonic butyrateproducing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-Transferase gene. Environ. Microbiol. 12(2), 304-314 (2010).
41. Feng ZM, Li TJ, Wu L, Xiao DF, Blachier F, Yin YL. Monosodium L-glutamate and dietary fat differently modify the composition of the intestinal microbiota in growing pigs. Obes. Facts 8(2), 87-100 (2015).
42. Kortman GA, Dutilh BE, Maathuis AJ, et al. Microbial metabolism shifts towards an adverse profile with supplementary iron in the TIM-2 in vitro model of the human colon. Front. Microbiol. 6, 1481 (2015).
43. Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes 7(1), 22-39 (2016).
44. Rossi M, Corradini C, Amaretti A, et al. Fermentation of fructooligosaccharides and inulin by bifidobacteria: a comparative study of pure and fecal cultures. Appl. Environ. Microbiol. 71(10), 6150-6158 (2005).
45. Walker AW, Duncan SH, Harmsen HJ, Holtrop G, Welling GW, Flint HJ. The species composition of the human intestinal microbiota differs between particle-Associated and liquid phase communities. Environ. Microbiol. 10(12), 3275-3283 (2008).
46. Matsumoto M, Benno Y. The relationship between microbiota and polyamine concentration in the human intestine: a pilot study. Microbiol. Immunol. 51(1), 25-35 2007).
47. Palmnäs MS, Cowan TE, Bomhof MR, et al. Low-dose aspartame consumption differentially affects gut microbiota-host metabolic interactions in the diet-induced obese rat. PLoS ONE 9(10), e109841 (2014).
48. Kazimierczak KA, Flint HJ, Scott KP. Comparative analysis of sequences flanking tet(W) resistance genes in multiple species of gut bacteria. Antimicrob. Agents Chemother. 50(8), 2632-2639 (2006).
49. Srinivasan V, Metcalf BJ, Knipe KM, et al. vanG element insertions within a conserved chromosomal site conferring vancomycin resistance to Streptococcus agalactiae and Streptococcus anginosus. mBio 5(4), e01386-e01314 (2014).
50. Simunek J, Brandysova V, Koppova I, Simunek J Jr . The antimicrobial action of chitosan, low molar mass chitosan, and chitooligosaccharides on human colonic bacteria. Folia Microbiol. (Praha) 57(4), 341-345 (2012).
51. Simunek J, Tishchenko G, Hodrova B, Bartonova H. Effect of chitosan on the growth of human colonic bacteria. Folia Microbiol. (Praha) 51(4), 306-308 (2006).
52. Stewardson AJ, Gaia N, Francois P, et al. Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota. Clin. Microbiol. Infect. 21(4), 344 e1-e11 (2015).
53. Morel FB, Oozeer R, Piloquet H, et al. Preweaning modulation of intestinal microbiota by oligosaccharides or amoxicillin can contribute to programming of adult microbiota in rats. Nutrition 31(3), 515-522 2015).
54. Janczyk P, Pieper R, Souffrant WB, Bimczok D, Rothkötter HJ, Smidt H. Parenteral long-Acting amoxicillin reduces intestinal bacterial community diversity in piglets even 5 weeks after the administration. ISME J. 1(2), 180-183 (2007).
55. Tajima K, Ohmori H, Aminov RI, Kobashi Y, Kawashima T. Fermented liquid feed enhances bacterial diversity in piglet intestine. Anaerobe 16(1), 6-11 (2010).
56. Zhang H, Sun J, Liu X, et al. Lactobacillus paracasei subsp. paracasei LC01 positively modulates intestinal microflora in healthy young adults. J. Microbiol. 51(6), 777-782 2013).
57. Berni Canani R, Sangwan N, Stefka AT, et al. Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants. ISME J. 10(3), 742-750 (2015).
58. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br. J. Nutr. 104(Suppl. 2), S1-S63 2010).
59. Everard A, Lazarevic V, Derrien M, et al. Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. Diabetes 60(11), 2775-2786 (2011).
60. Druart C, Alligier M, Salazar N, Neyrinck AM, Delzenne NM. Modulation of the gut microbiota by nutrients with prebiotic and probiotic properties. Adv. Nutr. 5(5), S624-S633 (2014).
61. Qin N, Zheng B, Yao J, et al. Influence of H7N9 virus infection and associated treatment on human gut microbiota. Sci. Rep. 5, 14771 (2015).
62. RajiliC-StojanoviC M, Shanahan F, Guarner F, de Vos WM. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm. Bowel Dis. 19(3), 481-488 (2013).
63. Tilg H, Danese S. Roseburia hominis: a novel guilty player in ulcerative colitis pathogenesis? Gut 63(8), 1204-1205 (2014).
64. Kumari R, Ahuja V, Paul J. Fluctuations in butyrate-producing bacteria in ulcerative colitis patients of North India. World J. Gastroenterol. 19(22), 3404-3414 (2013).
65. Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 47(3), 397-403 (2000).
66. Soret R, Chevalier J, De Coppet P, et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats. Gastroenterology 138(5), 1772-1782 2010).
67. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. FEMS Microbiol. Lett. 217(2), 133-139 (2002).
68. Louis P, Scott KP, Duncan SH, Flint HJ. Understanding the effects of diet on bacterial metabolism in the large intestine. J. Appl. Microbiol. 102(5), 1197-1208 2007).
69. Van den Abbeele P, Belzer C, Goossens M, et al. Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model. ISME J. 7(5), 949-961 2013).
70. Neville BA, Sheridan PO, Harris HM, et al. Pro-inflammatory flagellin proteins of prevalent motile commensal bacteria are variably abundant in the intestinal microbiome of elderly humans. PLoS ONE 8(7), e68919 (2013).
71. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331(6015), 337-341 (2011).
72. Machiels K, Sabino J, Vandermosten L, et al. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut 66(1), 79-88 (2015).
73. Vermeiren J, Van Den Abbeele P, Laukens D, et al. Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol. Ecol. 79(3), 685-696 (2012).
74. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63(8), 1275-1283 2014).
75. Chen L, Wang W, Zhou R, et al. Characteristics of fecal and mucosa-Associated microbiota in Chinese patients with inflammatory bowel disease. Medicine Baltimore) 93(8), e51 (2014).
76. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139(6), 1844-1854 e1841 2010).
77. Parthasarathy G, Chen J, Chen X, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation. Gastroenterology 150(2), 367e1-379e1 (2016).
78. Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipatedirritable bowel syndrome. Aliment. Pharmacol. Ther. 35(7), 828-838 (2012).
79. Rigsbee L, Agans R, Shankar V, et al. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 107(11), 1740-1751 (2012).
80. Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin. Exp. Gastroenterol. 8, 309-325 (2015).
81. Wang T, Cai G, Qiu Y, et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6(2), 320-329 (2012).
82. Zhu Q, Jin Z, Wu W, et al. Analysis of the intestinal lumen microbiota in an animal model of colorectal cancer. PLoS ONE 9(6), e90849 (2014).
83. Borges Canha M. Role of colonic microbiota in colorectal carcinogenesis: a systematic review. Rev. Esp. Enferm. Dig. 107(11), 659-671 (2015).
84. Geng J, Fan H, Tang X, Zhai H, Zhang Z. Diversified pattern of the human colorectal cancer microbiome. Gut Pathog. 5(1), 2 2013).
85. Hu S, Liu L, Chang EB, Wang JY, Raufman JP. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol. Cancer 14(1), 180 2015).
86. Kovatcheva-Datchary P, Arora T. Nutrition, the gut microbiome and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 27(1), 59-72 (2013).
87. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500(7464), 541-546 (2013).
88. Hoffmann TW, Pham HP, Bridonneau C, et al. Microorganisms linked to inflammatory bowel disease-Associated dysbiosis differentially impact host physiology in gnotobiotic mice. ISME J. 10(2), 460-477 2016).
89. Morgan XC, Kabakchiev B, Waldron L, et al. Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease. Genome Biol. 16, 67 (2015).
90. Neyrinck AM, Possemiers S, Druart C, et al. Prebiotic effects of wheat arabinoxylan related to the increase in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PLoS ONE 6(6), e20944 (2011).
91. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-Associated gut microbiome with increased capacity for energy harvest. Nature 444(7122), 1027-1031 (2006).
92. Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrateproducing bacteria in feces. Appl. Environ. Microbiol. 73(4), 1073-1078 (2007).
93. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc. Natl Acad. Sci. USA 102(31), 11070-11075 (2005).
94. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 444(7122), 1022-1023 (2006).
95. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(4), 913e917-916e917 2012).
96. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in Type 2 diabetes. Nature 490(7418), 55-60 2012).
97. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498(7452), 99-103 (2013).
98. Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 8(8), e71108 2013).
99. Wu X, Ma C, Han L, et al. Molecular characterisation of the faecal microbiota in patients with Type II diabetes. Curr. Microbiol. 61(1), 69-78 (2010).
100. Ciubotaru I, Green SJ, Kukreja S, Barengolts E. Significant differences in fecal microbiota are associated with various stages of glucose tolerance in African American male veterans. Transl. Res. 166(5), 401-411 (2015).
101. Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 11(7), 868-875 e861-e863 (2013).
102. Karlsson FH, Fak F, Nookaew I, et al. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat. Commun. 3, 1245 (2012).
103. Neyrinck AM, Possemiers S, Verstraete W, De Backer F, Cani PD, Delzenne NM. Dietary modulation of clostridial cluster XIVa gut bacteria (Roseburia spp) by chitin-glucan fiber improves host metabolic alterations induced by high-fat diet in mice. J. Nutr. Biochem. 23(1), 51-59 (2012).
104. Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 16(5), 559-564 2012).
105. Keim NL, Martin RJ. Dietary whole grain-microbiota interactions: insights into mechanisms for human health. Adv. Nutr. 5(5), 556-557 (2014).
106. Walker AW, Ince J, Duncan SH, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 5(2), 220-230 (2011).
107. Ordiz MI, May TD, Mihindukulasuriya K, et al. The effect of dietary resistant starch type 2 on the microbiota and markers of gut inflammation in rural Malawi children. Microbiome 3, 37 (2015).
108. Maukonen J, Simoes C, Saarela M. The currently used commercial DNA-extraction methods give different results of clostridial and actinobacterial populations derived from human fecal samples. FEMS Microbiol. Ecol. 79(3), 697-708 (2012).
109. Chen CC, Chen KJ, Kong MS, Chang HJ, Huang JL. Alterations in the gut microbiotas of children with food sensitization in early life. Pediatr. Allergy Immunol. 27(3), 254-262 2015).
110. Moreno-Indias I, Sanchez-Alcoholado L, Pérez-Martínez P, et al. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct. 7(4), 1775-1787 (2016).
111. Nielsen TS, Laerke HN, Theil PK, et al. Diets high in resistant starch and arabinoxylan modulate digestion processes and SCFA pool size in the large intestine and faecal microbial composition in pigs. Br. J. Nutr. 112(11), 1837-1849 (2014).
112. Scott KP, Antoine JM, Midtvedt T, van Hemert S. Manipulating the gut microbiota to maintain health and treat disease. Microb. Ecol. Health Dis. 26, 25877 2015).
113. Keshavarzian A, Green SJ, Engen PA, et al. Colonic bacterial composition in Parkinson's disease. Mov. Disord. 30(10), 1351-1360 2015).
114. Egshatyan L, Kashtanova D, Popenko A, et al. Gut microbiota and diet in patients with different glucose tolerance. Endocr. Connect. 5(1), 1-9 (2016).
115. Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut 63(9), 1513-1521 (2014).
116. Hedin CR, McCarthy NE, Louis P, et al. Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings. Gut 63(10), 1578-1586 (2014).
117. Wu N, Yang X, Zhang R, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb. Ecol. 66(2), 462-470 2013).
118. Wu T, Zhang Z, Liu B, et al. Gut microbiota dysbiosis and bacterial community assembly associated with cholesterol gallstones in large-scale study. BMC Genomics 14, 669 2013).
119. Larsen N, Vogensen FK, Gobel RJ, et al. Effect of Lactobacillus salivarius Ls-33 on fecal microbiota in obese adolescents. Clin. Nutr. 32(6), 935-940 (2013).
120. Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 303(6), G675-G685 (2012).
121. Frémont M, Coomans D, Massart S, De Meirleir K. High-Throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/ chronic fatigue syndrome patients. Anaerobe 22, 50-56 (2013).
122. Garn H, Neves JF, Blumberg RS, Renz H. Effect of barrier microbes on organ-based inflammation. J. Allergy Clin. Immunol. 131(6), 1465-1478 (2013).
123. Keren N, Konikoff FM, Paitan Y, et al. Interactions between the intestinal microbiota and bile acids in gallstones patients. Environ. Microbiol. Rep. 7(6), 874-880 (2015).